Biodegradable and Stimuli-Responsive Nanomaterials for Targeted Drug Delivery in Autoimmune Diseases

Journal of Functional Biomaterials, Journal Year: 2025, Volume and Issue: 16(1), P. 24 - 24

Published: Jan. 14, 2025

Autoimmune diseases present complex therapeutic challenges due to their chronic nature, systemic impact, and requirement for precise immunomodulation avoid adverse side effects. Recent advancements in biodegradable stimuli-responsive nanomaterials have opened new avenues targeted drug delivery systems capable of addressing these challenges. This review provides a comprehensive analysis state-of-the-art nanocarriers such as polymeric nanoparticles, liposomes, hydrogels engineered autoimmune therapies. These are designed degrade safely the body while releasing agents response specific stimuli, including pH, temperature, redox conditions, enzymatic activity. By achieving localized controlled release anti-inflammatory immunosuppressive agents, minimize toxicity enhance efficacy. We discuss underlying mechanisms nanomaterials, recent applications treating rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, design considerations essential clinical translation. Additionally, we address current challenges, biocompatibility, scalability, regulatory hurdles, well future directions integrating advanced nanotechnology with personalized medicine treatment. highlights transformative potential presenting them promising strategy advance precision improve patient outcomes disease management.

Language: Английский

---

Inflammatory Bowel Disease: Exploring Pathogenesis, Epidemiology, Conventional Therapies, and Advanced Nanoparticle Based Drug Delivery Systems

BioNanoScience, Journal Year: 2025, Volume and Issue: 15(1)

Published: Jan. 28, 2025

Language: Английский

---

Hydrogel derived from decellularized pig small intestine submucosa boosted the therapeutic effect of FGF-20 on TNBS-induced colitis in rats via restoring gut mucosal integrity

Materials Today Bio, Journal Year: 2025, Volume and Issue: unknown, P. 101783 - 101783

Published: April 1, 2025

Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by impaired intestinal mucosal barrier function, leading to persistent inflammation and tissue damage. Current therapies often fail address dysfunction, highlighting the need for innovative treatments. This study developed novel therapeutic strategy combining decellularized porcine small submucosa (D-SIS) with fibroblast growth factor 20 (FGF-20) promote repair restore integrity in TNBS-induced rat model. The D-SIS-based hydrogel, supplemented hyaluronic acid (HA), was designed enhance FGF-20 stability enable sustained drug release. Results showed that FGF-20-loaded hydrogel (MAF) exhibited excellent rheological properties, erosion resistance, controlled release, making it suitable rectal administration. In vitro cell experiments demonstrated MAF enhanced Caco-2 proliferation, migration, tight junction protein expression, restoring epithelial integrity. model, significantly reduced activity index (DAI) scores, attenuated inflammation, restored morphology. Additionally, promoted goblet regeneration, mucus secretion, upregulated stem markers, indicating its ability both barriers. conclusion, represents promising approach UC regenerative properties of bioactive support D-SIS.

Language: Английский

---

Dual-action microparticles for ulcerative colitis: Cellulose nanofibers-enhanced delivery of 5-ASA and probiotics

International Journal of Biological Macromolecules, Journal Year: 2024, Volume and Issue: unknown, P. 139060 - 139060

Published: Dec. 1, 2024

Language: Английский

---

Azo-linked 5-ASA-coumarin prodrug: fluorescent tracking for colonic drug release in UC treatment

Talanta, Journal Year: 2024, Volume and Issue: 284, P. 127277 - 127277

Published: Nov. 22, 2024

Language: Английский

---